Meeting
2019 ASCO Annual Meeting
Results from a phase Ib/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC).
Authors
Mamta Parikh
University of California Davis Comprehensive Cancer Center, Sacramento, CA
Mamta Parikh , Daniel Robles , Chong-xian Pan , Primo Lara Jr., Joy C Yang , Allen Gao , Christopher P. Evans
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02339168
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5054)
DOI
10.1200/JCO.2019.37.15_suppl.5054
Abstract #
5054
Poster Bd #
166
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Enzalutamide and metformin combination therapy to overcome autophagy resistance in castration resistant prostate cancer (CRPC): Current results from a phase I study.
First Author: Mamta Parikh
Poster
2016 ASCO Annual Meeting
Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202.
First Author: John Paul Flores
Poster
2020 Genitourinary Cancers Symposium
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study.
First Author: Marit Vermunt
Poster
2018 ASCO Annual Meeting
Investigation of metformin (MET) in patients with castration resistant prostate cancer (CRPC) in combination with enzalutamide (ENZ) vs. ENZ alone: A randomized, open label, phase 2 trial. SAKK 08/14—IMPROVE.
First Author: Christian Alexander Rothermundt